Healthcare -
Medical - Devices - NYSE - GB
$ 30.17
0.971 %
$ 13.2 B
Market Cap
32.1
P/E
1. INTRINSIC VALUE
Balance Sheet
Smith & Nephew plc
| Current Assets | 4.42 B |
| Cash & Short-Term Investments | 619 M |
| Receivables | 1.21 B |
| Other Current Assets | 2.6 B |
| Non-Current Assets | 5.93 B |
| Long-Term Investments | 16 M |
| PP&E | 1.42 B |
| Other Non-Current Assets | 4.5 B |
| Current Liabilities | 1.53 B |
| Accounts Payable | 1.08 B |
| Short-Term Debt | 63 M |
| Other Current Liabilities | 386 M |
| Non-Current Liabilities | 3.56 B |
| Long-Term Debt | 3.26 B |
| Other Non-Current Liabilities | 300 M |
EFFICIENCY
Earnings Waterfall
Smith & Nephew plc
| Revenue | 5.81 B |
| Cost Of Revenue | 1.76 B |
| Gross Profit | 4.05 B |
| Operating Expenses | 3.39 B |
| Operating Income | 657 M |
| Other Expenses | 245 M |
| Net Income | 412 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Smith & Nephew plc
| Net Income | 412 M |
| Depreciation & Amortization | 580 M |
| Capital Expenditures | -381 M |
| Stock-Based Compensation | 40 M |
| Change in Working Capital | -123 M |
| Others | 78 M |
| Free Cash Flow | 606 M |
Wall Street Analysts Price Targets
Smith & Nephew plc
Wall Street analysts predict an average 1-year price target for SNN of $27 , with forecasts ranging from
a
low of
$27 to a high of $27 .
SNN Lowest Price Target
Wall Street Target
27 USD
-10.51%
SNN Average Price Target
Wall Street Target
27 USD
-10.51%
SNN Highest Price Target
Wall Street Target
27 USD
-10.51%
4. DIVIDEND
ANALYSIS
0.00%
DIVIDEND YIELD
0.462 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Smith & Nephew plc
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
SNN or ESLOY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Products sector have probably already heard of Smith & Nephew (SNN) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two stocks is more attractive to value investors?
zacks.com
- 2 weeks ago
Are Investors Undervaluing Smith & Nephew SNATS (SNN) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
- 2 weeks ago
Smith+Nephew expands market-leading fixation strength of Q-FIX™ All-Suture Anchor portfolio with new knotless option
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the release of its Q-FIX KNOTLESS All-Suture Anchor for soft tissue-to-bone fixation indications across multiple joint spaces including Shoulder, Hip, and Foot & Ankle.
globenewswire.com
- 2 weeks ago
SNN Expands Orthopedic Portfolio With Advanced Tibia Nailing System
Smith + Nephew launches TRIGEN MAX, the only tibia nailing system with side-specific nails for precise, low-impact fracture repair.
zacks.com
- 1 month ago
SNN vs. GEHC: Which Stock Is the Better Value Option?
Investors interested in Medical - Products stocks are likely familiar with Smith & Nephew (SNN) and GE HealthCare Technologies (GEHC). But which of these two stocks is more attractive to value investors?
zacks.com
- 1 month ago
Is Smith & Nephew SNATS (SNN) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
zacks.com
- 1 month ago
Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings ‘next-level nailing' to trauma surgeons repairing tibial fractures
The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options.1, 2 The TRIGEN MAX Tibia Nailing System aims to streamline operative procedures and provide efficiency through surgeon-centered design of components and instrumentation, including: Two-piece modular drop system to help when using ancillary instruments and aid visualization.
globenewswire.com
- 1 month ago
Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.
globenewswire.com
- 1 month ago
Smith+Nephew Stock May Gain From Strategic Deal With Standard Health
SNN teams with Standard Health to launch the United Kingdom's first orthopedic ASC, aiming to boost surgical efficiency and drive growth.
zacks.com
- 1 month ago
Smith+Nephew and Standard Health partner on first Orthopaedic Ambulatory Surgery Centre in the UK
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces a strategic partnership with Standard Health www.standardhealth.co.uk to support the development of the first-ever Orthopaedic Ambulatory Surgery Centre in the UK. Based in Poole, Dorset, the new centre will offer NHS and private patients access to leading joint repair and replacement technology for conditions such as rotator cuff repair, ACL reconstruction, knee and hip replacements, and foot & ankle/hand & wrist procedures.
globenewswire.com
- 1 month ago
New medial stabilized insert for Smith+Nephew's LEGION™ Total Knee System designed to improve kinematics, stability and procedural versatility
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the introduction of a new medial stabilized insert for its LEGION Total Knee System (TKS). Medial stabilized inserts are seeing a steep rise in popularity, growing from 4% of Total Knee Arthroplasty procedures in 2018 to 32% in 2023.1
globenewswire.com
- 1 month ago
Smith+Nephew awarded contract to provide Negative Pressure Wound Therapy systems to the United States Department of Defense
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, has been selected to provide its RENASYS◊ TOUCH Negative Pressure Wound Therapy (NPWT) Systems under a single award, 10-year* contract for up to $75 million by the U.S. Department of Defense (DoD) through the Defense Logistics Agency (DLA).
globenewswire.com
- 2 months ago
8. Profile
Summary
Smith & Nephew plc SNN
COUNTRY
GB
INDUSTRY
Medical - Devices
MARKET CAP
$ 13.2 B
Dividend Yield
0.00%
Description
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
Contact
Building 5, Watford, WD18 8YE
https://www.smith-nephew.com
IPO
Date
Nov. 16, 1999
Employees
17349
Officers
Mr. Philip G. Cowdy
Chief Corporate Development & Corporate Affairs Officer
Mr. Charles Reynolds
Head of Corporate Communication
Dr. Deepak S. Nath Ph.D.
Chief Executive Officer & Director
Ms. Helen Barraclough
Group General Counsel & Company Secretary
Dr. Vasant Padmanabhan Ph.D.
President of Research & Development and Ear, Nose & Throat
Mr. Paul Connolly
President of Global Operations
Ms. Alison Parkes
Chief Compliance Officer & Compliance APAC
Ms. Elga Lohler
Chief Human Resources Officer
Mr. Andrew Swift
Head of Investor Relations
Mr. John Terence Rogers
Chief Financial Officer & Executive Director